Therapeutic Targeting of the Proteasome in Disease

In honor of Julian Adams, Ph.D., Kenneth C. Anderson M.D., Alfred L. Goldberg, Ph.D. , and Paul G. Richardson, M.D. for their discovery, preclinical and clinical development of Bortezomib (Velcade) to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Julian Adams

Julian Adams | 2012 Recipient

For the discovery, preclinical and clinical development of  bortezomib to FDA approval and front line therapy for the treatment of patients with multiple myeloma.

Julian Adams, PhD is President of Research and Development at Infinity Pharmaceuticals. Adams is responsible for the full spectrum of Infinity’s drug discovery, preclinical, and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, he was the Senior Vice President of Drug Discovery and Development at Millennium Pharmaceuticals. In this capacity he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999 where he was Senior Vice President of Research and Development. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, Executive Vice President of Research and Development, and a member of the Board of Directors. Earlier in his career, Adams served in various positions, including Director of Medicinal Chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV. Also, from 1982–
1987, he was a medicinal chemist at Merck.

Adams has received many awards, including the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. He is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004.

Adams received his BS from McGill University and his PhD from the Massachusetts Institute of Technology in the field of synthetic organic chemistry.

Opening Remarks

Jeffrey S. Flier, MD

Dean of the Faculty of Medicine, Harvard University

Joan S. Brugge, PhD

Louise Foote Pfeiffer Professor of Cell Biology and Chair of the Department of Cell Biology, Harvard Medical School

Alfred L. Goldberg, PhD

Professor of Cell Biology, Harvard Medical School Functions of the Proteasome: From Protein Degradation to Drug Development

Julian Adams, PhD

President, Research and Development, Infinity Pharmaceuticals The Discovery and Development of Bortezomib

Kenneth C. Anderson, MD

Kraft Family Professor of Medicine, Harvard Medical School, Director of the LeBow Institute for Myeloma Therapeutics and Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute Bench to Bedside Translation of Proteasome Inhibitor Therapy in Multiple Myeloma

Paul G. Richardson, MD

Associate Professor of Medicine, Harvard Medical School and Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute The Clinical Development of Bortezomib in Multiple Myeloma: from Single Agent to Combinations and Beyond

Sign up to receive updates

Sign up to receive updates

Past Symposia

For questions about the prize, please contact us.

Contact Us
I am very much humbled by all the great scientists before us. Although our initial mapping of the CF gene to chromosome 7, followed by the gene identification work, was the first step in defining the basic defect of CF, difficult as it was, I am happy that the award also recognizes those people who have spent their lives improving the health of patients with this devastating disease, studying its pathophysiology and devising effective treatments. I would be remiss if I did not mention also the contributions of Jack Riordan, Johanna Rommens and Batsheva Kerem and the rest of my Toronto team in the CF gene cloning effort.
- Lap-chee Tsui

Lap-chee Tsui | 2018 Recipient

Professor Lap-Chee Tsui is the Founding President of the Academy of Sciences of Hong Kong, President of the Victor and William Fung Foundation, Director of Qiushi Academy for Advanced Studies and Master of the Residential College of International Campus, Zhejiang University.  He is also the University of Toronto’s Emeritus University Professor.

He is the immediate-past Vice Chancellor of The University of Hong Kong, prior to which, he was Geneticist-in-Chief at the Hospital for Sick Children in Toronto and University Professor at University of Toronto, Canada
He received his Bachelor and Master degrees from the Chinese University of Hong Kong and his PhD from University of Pittsburgh.  He is world renowned for his research work in human genetics and genomics, including the identification of the gene for Cystic Fibrosis, which is an important piece of work in defining the basic defect of the disorder and in human genetic disease research as a whole. His other contributions include the cloning and characterization of mammalian crystallin genes and a comprehensive mapping and characterization of human chromosome 7.

Professor Tsui has over 300 peer-reviewed scientific publications and 65 invited book chapters.  He is the recipient of many national/international prizes, and is a Fellow of Royal Society of Canada, Royal Society of London and Academia Sinica.  He is a Associate Member of the National Academy of Sciences USA, a Foreign Member of Chinese Academy of Sciences, and is a Canadian Medical Hall of Fame Laureate.  His other awards include 15 honorary doctoral degrees, the Orders of Canada and Ontario, and the Grand Bauhinia Medal and Gold Bauhinia Star, and Justice of the Peace from Hong Kong.

 View Past Recipients